Lava and Janssen announces collaboration to develop bi-specific gamma-delta T-cell engager therapeutics
May 18, 2020Lava Therapeutics B.V. (spin-off Amsterdam UMC, location VUmc) announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson & Johnson Innovation.
“We are excited to enter into this collaboration with Janssen, a global innovator and leader in the development of new medicines,” said Stephen Hurly, chief executive officer of Lava Therapeutics. “We strongly believe in the strength of our bispecific gamma-delta T cell engager platform and are committed to creating highly potent, target-specific therapeutics with increased durability and safety over current T cell-based approaches.”
Under the terms of the agreement, Lava Therapeutics will perform discovery and product development activities, and is eligible to receive an undisclosed financial package consisting of an upfront payment and potential development and commercial milestones, and future tiered royalties.
About Lava Therapeutics
Lava Therapeutics, B.V., is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers. The company’s first-in-class immuno-oncology approach activates Vγ9Vδ2 T cells upon binding to membrane-expressed tumor targets. Lava was founded in 2016 based on intellectual property originating from the Amsterdam University Medical Center, and is backed by Lupus Ventures, Biox Biosciences, Versant Ventures, Gilde Healthcare and MRL Ventures Fund. The company has established a highly experienced antibody research and development team located in Utrecht, the Netherlands (headquarters) and Philadelphia. For more information, please visit www.lavatherapeutics.com.
More news
Funding from KWF for palliative cancer patients in meaning-making at home
The diagnosis of incurable cancer profoundly disrupts patients’ lives, often causing existential crises and a sense of lost purpose. The KWF-funded project “In Search of Stories” (ISOS) aimed to support these patients by partnering them with spiritual counsellors and professional artists. This co-creation process proved highly beneficial. New funding from KWF Dutch Cancer Society supports […]
News
Impact in education and beyond: VU researcher Laura Rupp secures Comenius Leadership Fellow grant
Laura Rupp has been awarded the Comenius Leadership Fellow grant for a three-year period. This grant of 500,000 Euros, will fund a project titled “Global English and International Dutch on the VU Campus”. Over the years, Rupp has successfully reached more than 100,000 people online worldwide, teaching how to understand diverse English accents and speak […]
News
Max Nieuwdorp’s innovative research on gut microbes: a path to combat fatty liver disease
Internist Max Nieuwdorp, of Amsterdam UMC, discovered a few years ago that the microorganisms in the intestines of many overweight people produce alcohol to an increased extent. Breaking down excessive alcohol leads to fatty liver disease, which in turn poses a risk of serious conditions such as diabetes and cardiovascular disease. Nieuwdorp has now received an ERC Advanced Grant of 2.5 million euros for a major study into the underlying causes of this excessive alcohol production.
News